Life Spine 
said that the FDA has granted 510(k) market clearance for the company’s Prolift lateral expandable spacer system.
The system features minimal insertion height and controlled, in situ expansion, which are critical components in a minimally invasive expandable lateral interbody fusion procedure, according to the Huntley, Ill.-based company.
“The Prolift lateral expandable spacer system is a significant addition to Life Spine’s rapidly growing expandable portfolio,” Life Spine chief operating officer Rich Mueller said in a news release. “The device will be available in a multitude of footprints and lordotic options, allows for post-packing in situ, has anatomically convex endplates and has Life Spine’s proprietary Osseo-Loc surface technology.”
In April, the company announced that the Prolift system saw sales growth of 40% in the first quarter of 2019 over the same quarter last year. Sales were driven by continued clinical review and full adoption by surgeons and hospitals, the company said.
